drugset / Trial / NCT01789528

A Study to Investigate the Effect of Administration of Ceftazidime-avibactam (CAZ-AVI) and Ceftaroline Fosamil -Avibactam (CXL) on the Intestinal Flora of Healthy Volunteers

NCT01789528

Phase 1 Completed 48 enrolled Pfizer
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to investigate the effect of administration of CAZ-AVI and CXL on the intestinal flora of male and female healthy volunteers after multiple administrations over 7 days. An assessment of the effect on intestinal flora is an important aspect to understand for the safe clinical use of the investigational products and is expected by regulatory agencies.

Timeline

Start
2013-08
Primary completion
2014-03
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ceftaroline fosamil Other / unclassified 600 mg Intravenous
Subject Ceftazidime Small molecule 2000 mg Intravenous
Subject avibactam Small molecule 500 mg Intravenous
Subject avibactam Small molecule 600 mg Intravenous

Indications

No indication recorded.